Cable Hill Partners’s Sarepta Therapeutics SRPT Stock Holding History

Cable Hill Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-29	Closed	-$3K	–	613
2019 Q1	$3K	Hold	29	–	–	﹤0.01%	716
2018 Q4	$3K	Hold	29	–	–	﹤0.01%	676
2018 Q3	$4K	Sell	29 -25	-46%	-$3.42K	﹤0.01%	627
2018 Q2	$7K	Sell	54 -18	-25%	-$1.7K	﹤0.01%	570
2018 Q1	$5K	Sell	72 -121	-63%	-$8.07K	﹤0.01%	678
2017 Q4	$11K	Hold	193	–	–	﹤0.01%	558
2017 Q3	$9K	Buy	193 +87	+82%	+$3.48K	﹤0.01%	610
2017 Q2	$4K	Hold	106	–	–	﹤0.01%	605
2017 Q1	$3K	Buy	+106	New	+$3.28K	﹤0.01%	638
2016 Q4	–	Sell	-111	Closed	-$7K	–	902
2016 Q3	$7K	Buy	+111	New	+$3.36K	0.01%	507

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cable Hill Partners's SRPT Position: Q2 2019 in Review

Cable Hill Partners sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 29 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in SRPT in Q3 2016 and held it in 10 quarters. The position peaked at $11K in Q4 2017. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

Cable Hill Partners reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 29 Sarepta Therapeutics shares in Q2 2019, an estimated $3K.
Cable Hill Partners first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 10 quarters.
Cable Hill Partners's Sarepta Therapeutics position peaked at $11K in Q4 2017.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.